AbCellera Biologics, Inc. ABCL 深 沪
等待开盘 05-21 09:30:00 美东时间
4.5671
+0.517
+12.77%
华盛通- 最 高4.5999
- 今 开4.10
- 成交量 551.61万股
- 最 低 4.05
- 昨 收 4.05
- 总市值 13.95亿
- 52周最高 6.515
- 市盈率 静 --
- 换手率 1.81%
- 52周最低 2.02
- 委 比 -20.59%
- 总股本 3.05亿
- 历史最高 71.91
- 量 比 1.31
- 振 幅 13.58%
- 历史最低 1.8906
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多电话会总结 ｜ AbCellera(ABCL)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据AbCellera业绩会实录，以下是2026年第一季度财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 第一季度营收800万美元，同比增长100%（2025年同期为400万美元），主要来源为研究费收入。 **盈利状况：** 净亏损4300万美元，同比收窄6.5%（2025年同期净亏损4600万美元）。每股亏损0.14美元（基本和稀释）。 **现金流状况：** 经营活动现金流出3400万美元；净现金流出3000万美元。期末现金及等价物约5.3亿美元，现金、现金等价物及有价证券总计5.31亿美元。 **费用控制：** 研发费用4700万美
05-12 12:26
AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year. The company reported
05-12 04:08
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $7.
05-06 01:45
AbCellera To Disclose Interim Results From Phase 1 Portion Of Its Study Of ABCL635, Including Observed Safety Profile, Pharmacokinetic, And Pharmacodynamic Target Engagement Data, During Q1 Earnings Call On May 11
AbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement
04-20 21:06
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11
Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $11.
04-10 20:20
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics reported financial results for 2025, highlighting a cash runway extending into Q2 2027. The company announced FDA clearance for its mutant-selective JAK2V617F inhibitor PRT12396 and plans to initiate Phase 1 trials for PRT12396 in high-risk PV and MF patients in Q2 2026. Additionally, the KAT6A degrader PRT13722 is expected to enter clinical development later in 2026. Notably, R&D expenses decreased, reflecting reduced costs ...
03-10 11:01
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts
Abcellera Biologics, Inc. (($ABCL)) has held its Q4 earnings call. Read on for ...
02-26 08:26
